Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3199 results found
Expand All
Apply All
3199 results found

Senate Letter to Administration to Reject RFS Waivers
Share
Agriculture & Environment, Sustainable Fuels  •  Letters, Testimony & Comments  •  May 7, 2020
We urge you to direct the EPA to reject all calls to waive the RFS. The RFS is more important now than ever as farmers, the biofuel sector, and rural America struggle to remain operating amid the COVID-19 crisis.
Read More

"Herd" immunity
Share
Bio.News  •  May 7, 2020
Today we have another must-listen episode of the I AM BIO Podcast about a fascinating company using animal biotech to save human lives. More on that, plus updates on more BIO members’ COVID-19 treatment breakthroughs and the latest news from Washington, in about 530 words, 3 and a half minutes.
Read More

A few things to know about coronavirus R&D
Share
Bio.News  •  May 6, 2020
What can we expect in terms of coronavirus treatments and vaccines—and when? BIO’s Jim Greenwood and Merck’s Julie Gerberding have some insight on these questions, and how the industry’s rising to a very big challenge. We’re also looking at why you shouldn’t get TOO excited about lower levels of carbon emissions, and who’s calling Congress “a highly efficient virus spreading machine,” in just under 900 words, about 4 minutes, 22 seconds.
Read More

New online IP marketplace will foster collaboration
Share
Bio.News  •  May 5, 2020
Vir and Alnylam have chosen their top pick for a COVID-19 therapeutic candidate, and they’re getting ready to start clinical trials. This is yet another great example of the industry’s unprecedented level of collaboration. Today, we've got news on a new IP platform that will facilitate this kind of collaboration, as well as how biotech can help ensure the sustainability of the world’s food supply, pandemic or not, in 770 words, just under 4 minutes.
Read More

New Online IP Marketplace Will Foster Collaboration in Race to Eradicate COVID-19
Share
Intellectual Property, Human Health  •  Press Release  •  May 4, 2020
To help in the response to the coronavirus pandemic, the U.S. Patent and Trademark Office today launched a new online platform, called “Patents 4 Partnerships,” to share patent information for various technologies to facilitate greater collaboration across industries. Tom DiLenge, President of BIO’s Advocacy, Law & Public Policy Division, issued the following statement in response: “The U.S. Patent and Trademark Office has taken an important step to support critical research collaboration during this pandemic. Our nation’s intellectual property protections provide a strong foundation for the rapid response against COVID-19, as thousands of scientists in hundreds of biopharmaceutical companies work around the clock to develop treatments and vaccines for this deadly virus. Our researchers are working together like never before, sharing knowledge and resources to accelerate R&D solutions. And all of this collaboration is possible because of the strong intellectual property system we have in place today, not in spite of it.  “To advance the discovery of life-saving medicines, the biopharmaceutical industry is committed to robust collaboration both across the industry and with public and nonprofit partners. This new online platform will help us achieve our shared goal of eradicating COVID-19 as quickly as possible.”   Learn more about some of the latest scientific advancements in the fight against COVID-19 at www.bio.org/coronavirus.  ###
Read More

Gilead’s good news
Share
Bio.News  •  May 4, 2020
The Senate is back in Washington today, and we’re starting the week with a deeper dive into the good news from Gilead. But we’re also looking at the link between air pollution and COVID-19 deaths—and those who are still denying it. Here are 855 words, about 4 minutes, 15 seconds.
Read More

Out of the bat cave, into the virus fire
Share
Bio.News  •  May 1, 2020
Happy Friday. In case you missed it, Gilead Chairman and CEO Daniel O’Day joined NBC’s Savanah Guthrie on TODAY to discuss the latest development with the company’s experimental treatment remdesivir. As Guthrie notes during the interview, “We are in the midst of a pandemic and humanity is literally depending on companies like yours.” Watch the segment here.We’re taking you into the weekend with a look at why it’s more important than ever to continue research into zoonotic diseases—and what it will take to get us back to work and normal life after the pandemic. Here are 780 words, or 4 minutes, to start your weekend.
Read More

Out of the bat cave, into the virus fire
Share
Bio.News  •  May 1, 2020
Happy Friday. In case you missed it, Gilead Chairman and CEO Daniel O’Day joined NBC’s Savanah Guthrie on TODAY to discuss the latest development with the company’s experimental treatment remdesivir. As Guthrie notes during the interview, “We are in the midst of a pandemic and humanity is literally depending on companies like yours.” Watch the segment here.We’re taking you into the weekend with a look at why it’s more important than ever to continue research into zoonotic diseases—and what it will take to get us back to work and normal life after the pandemic. Here are 780 words, or 4 minutes, to start your weekend.
Read More

This technology might block and destroy the coronavirus genome
Share
Bio.News  •  April 30, 2020
Just two more days until the weekend. Today, we have a new episode of the I AM BIO Podcast, featuring a company using breakthrough RNA technology that might be able to block and destroy the genome of the coronavirus. We’re also looking at how biotech could save your summer stone fruits. Here are just under 800 words, just under 4 minutes.
Read More

Thank essential workers – and PPE – for tonight’s pork chops
Share
Bio.News  •  April 29, 2020
JUST IN: For those just getting out of bed, STAT News is reporting that COVID-19 patients are responding to Gilead’s remdesivir – a sign of hope on the horizon. We also have news from the Trump administration on the meat industry and essential workers—and why PPE is so important. And, we’re closing out World Immunization Awareness Week with some big news on a COVID-19 vaccine. Here are about 965 words, just under 5 minutes.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 236
  • 237
  • 238
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO